NANO MRNALtd Past Earnings Performance
Past criteria checks 0/6
NANO MRNALtd has been growing earnings at an average annual rate of 8.8%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 74.8% per year.
Key information
8.8%
Earnings growth rate
9.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -74.8% |
| Return on equity | -26.9% |
| Net Margin | -1,609.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How NANO MRNALtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 51 | -821 | 115 | 647 |
| 30 Jun 24 | 77 | -651 | 162 | 647 |
| 31 Mar 24 | 135 | -780 | 328 | 647 |
| 31 Dec 23 | 164 | -1,048 | -147 | 1,120 |
| 30 Sep 23 | 202 | -900 | 109 | 1,120 |
| 31 Mar 23 | 202 | -1,310 | 285 | 1,120 |
Quality Earnings: 3NQ is currently unprofitable.
Growing Profit Margin: 3NQ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 3NQ's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 3NQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3NQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 3NQ has a negative Return on Equity (-26.86%), as it is currently unprofitable.